Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An early access program for Naxitamab in Europe

Next Previous
Search
Trial Profile

An early access program for Naxitamab in Europe

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 23 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naxitamab (Primary)
  • Indications Neuroblastoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Dec 2022 New trial record
    • 21 Dec 2022 According to a Y-mAbs Therapeutics media release, company has entered into a distribution agreement with WEP Clinical Ltd. in connection with an early access program for DANYELZA (naxitamab-gqgk) 40mg/10mL Injection in Europe.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top